Some recent trends and progress in the physics and biophysics of neutron capture therapy

Abstract

Building upon earlier American efforts in the field as well as upon continuing research in Japan, clinical trials of epithermal-neutron boron neutron capture therapy (BNCT) for glioblastoma multiforme and for malignant melanoma began in the U.S. in 1994 and in Europe in 1997. These trials, while not yet conclusive, are showing promise and have stimulated the development of improved reactor-based epithermal-neutron beam facilities as well as several types of accelerator-based neutron sources for future trials of this modality worldwide. Developments in computational dosimetry and treatment planning techniques and software suitable for BNCT applications have also continued apace. Interest in various applications of neutron capture techniques to other malignancies as well as to some non-malignant conditions such as rheumatoid arthritis is also accelerating.